Akili (AKLI) & Its Competitors Critical Review

Akili (NASDAQ:AKLIGet Free Report) is one of 209 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its peers? We will compare Akili to related businesses based on the strength of its risk, institutional ownership, valuation, analyst recommendations, earnings, profitability and dividends.

Valuation and Earnings

This table compares Akili and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Akili $320,000.00 -$7.96 million -7.64
Akili Competitors $948.49 million $53.57 million 31.83

Akili’s peers have higher revenue and earnings than Akili. Akili is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Akili has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Akili’s peers have a beta of 1.35, suggesting that their average share price is 35% more volatile than the S&P 500.

Institutional and Insider Ownership

53.1% of Akili shares are owned by institutional investors. Comparatively, 46.4% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 20.4% of Akili shares are owned by insiders. Comparatively, 14.6% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.


This table compares Akili and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Akili 940.71% -72.28% -54.30%
Akili Competitors -589.61% -330.22% -30.83%

Analyst Ratings

This is a breakdown of current ratings and target prices for Akili and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akili 0 2 1 0 2.33
Akili Competitors 1242 3628 7463 161 2.52

Akili currently has a consensus target price of $3.50, suggesting a potential upside of 227.10%. As a group, “Surgical & medical instruments” companies have a potential upside of 33.02%. Given Akili’s higher possible upside, research analysts plainly believe Akili is more favorable than its peers.


Akili peers beat Akili on 8 of the 13 factors compared.

About Akili

(Get Free Report)

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. Akili, Inc. was founded in 2011 and is headquartered in Boston, Massachusetts.

Receive News & Ratings for Akili Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akili and related companies with MarketBeat.com's FREE daily email newsletter.